CD8+ T-cell activation in HIV-1-infected patients experiencing transient low-level viremia during antiretroviral therapy

Journal of Acquired Immune Deficiency Syndromes

Volumn 63, Issue 1, 2013, Pages 101-104

  Taiwo, Babafemi ^a   Hunt, Peter W ^b   Gandhi, Rajesh T ^c   Ellingson, Andrew ^d   McKenna, Matthew ^d   Jacobson, Jeffrey M ^e   Gripshover, Barbara ^f   Bosch, Ronald J ^d  

^a NORTHWESTERN UNIVERSITY   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

^d CENTER FOR BIOSTATISTICS IN AIDS RESEARCH   (United States)

^e DREXEL UNIVERSITY COLLEGE OF MEDICINE   (United States)

^f CASE WESTERN RESERVE UNIVERSITY   (United States)

Author keywords

activation; blip; CD8+; immune; low level; viremia

Indexed keywords

ANTIRETROVIRUS AGENT; CD38 ANTIGEN; HLA DR ANTIGEN; VIRUS RNA;

ADULT; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CROSS-SECTIONAL STUDY; DISEASE ASSOCIATION; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; IMMUNE RESPONSE; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; PREDICTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; T LYMPHOCYTE ACTIVATION; TRANSIENT LOW LEVEL VIREMIA; VIREMIA;

ADULT; ANTIGENS, CD38; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; FEMALE; HIV INFECTIONS; HIV-1; HLA-DR ANTIGENS; HUMANS; LYMPHOCYTE ACTIVATION; MALE; MEMBRANE GLYCOPROTEINS; RNA, VIRAL; TREATMENT OUTCOME; VIREMIA;

EID: 84876286480     PISSN: 15254135     EISSN: 10779450     Source Type: Journal    
DOI: 10.1097/QAI.0b013e3182895af4     Document Type: Article

References (26)

1. Sungkanuparph S, Overton ET, Seyfried W, et al. Intermittent episodes of detectable HIV viremia in patients receiving nonnucleoside reverse-transcriptase inhibitor-based or protease inhibitor-based highly active antiretroviral therapy regimens are equivalent in incidence and prognosis. Clin Infect Dis. 2005;41:1326-1332.
2. Di Mascio M, Markowitz M, Louie M, et al. Dynamics of intermittent viremia during highly active antiretroviral therapy in patients who initiate therapy during chronic versus acute and early HIV type 1 infection. J Virol. 2004;78:10566-10573.
3. Nettles RE, Kieffer TL, Kwon P, et al. Intermittent HIV-1 viremia (blips) and drug resistance in patients receiving HAART. JAMA. 2005;293:817-829.
4. Grennan JT, Loutfy MR, Su D, et al. The magnitude of virologic blips is associated with a higher risk for virologic rebound in HIV-infected individuals: a recurrent events analysis. J Infect Dis. 2012;205:1230-1238.
5. Miller LG, Golin CE, Liu H, et al. No evidence of an association between transient HIV viremia (blips) and lower adherence to the antiretroviral medication regimen. J Infect Dis. 2004;189:1487-1496.
6. Stosor V, Palella FJ, Berzins B, et al. Transient viremia in HIV infected patients and use of plasma preparation tubes. Clin Infect Dis. 2005;41: 1671-1674.
7. Doyle T, Smith C, Vitiello P, et al. Plasma HIV-1 RNA detection below 50 copies/mL and risk of virologic rebound in patients receiving highly active antiretroviral therapy. Clin Infect Dis. 2012;54:729-737.
8. Easterbrook PJ, Ives N, Waters A, et al. The natural history and clinical significance of intermittent viraemia in patients with initial viral suppression to, 400 copies/ml. AIDS. 2002;16:1521-1527.
9. Maggiolo F, Callegaro A, Cologni G, et al. Ultrasensitive assessment of residual low-level HIV viremia in HAART-treated patients and risk of virological failure. J Acquir Immune Defic Syndr. 2012;60:473-482.
10. Li JZ, Gallien S, Do TD, et al. Prevalence and significance of HIV-1 drug resistance mutations among patients on antiretroviral therapy with detectable low-level viremia. Antimicrob Agents Chemother. 2012;56:5998-6000.
11. Cohen Stuart JWT, Hazebergh MD, Hamman D, et al. The dominant source of CD4+ and CD8+ T-cell activation in HIV infection is antigenic stimulation. J Acquire Immune Defic Syndr. 2000;25:203-211.
12. Plaeger SF, Collins BS, Musib R, et al. Immune activation in the path-ogenesis of treated chronic HIV disease: a workshop summary. AIDS Res Hum Retroviruses. 2012;28:469-477.
13. Sandler NG, Douek DC. Microbial translocation in HIV infection: causes, consequences and treatment opportunities. Nat Rev Microbiol. 2012;10:655-666.
14. French MA, King MS, Tschampa JM, et al. Serum immune activation markers are persistently increased in patients with HIV infection after 6 years of antiretroviral therapy despite suppression of viral replication and reconstitution of CD4+ T-cells. J Infect Dis. 2009;200:1212-1215.
15. Hunt PW, Martin JN, Sinclair E, et al. T-cell activation is associated with lower CD4+ T-cell gains in human immunodeficiency virus-infected patients with sustained viral suppression during antiretroviral therapy. J Infect Dis. 2003;187:1534-1543.
16. Robbins GK, Spritzler JG, Chan ES, et al. Incomplete reconstitution of T-cell subsets on combination antiretroviral therapy in the AIDS Clinical Trials Group protocol 384. Clin Infect Dis. 2009;48:350-361.
17. Gandhi RT, Spritzler J, Chan E, et al. Effect of baseline-and treatment-related factors on immunologic recovery after initiation of antiretroviral therapy in HIV-1-positive subjects: results from ACTG 384. J Acquir Immune Defic Syndr. 2006;42:426-434.
18. Robbins GK, De Gruttola V, Shafer RW, et al. Comparison of sequential three-drug regimens as initial therapy for HIV-1 infection. N Engl J Med. 2003;349:2304-2315.
19. Shafer RW, Smeaton LM, Robbins GK, et al. Comparisons of four-drug regimens and pairs of sequential three-drug regimens as initial therapy for HIV-1 infection. N Engl J Med. 2003;349:2304-2315.
20. Smurzynski M, Collier AC, Koletar SL, et al. AIDS clinical trials group longitudinal linked randomized trials (ALLRT): rationale, design, and baseline characteristics. HIV Clin Trials. 2008;9:269-282.
21. Flynn PM, Rudy BJ, Douglas SD, et al. Virologic and immunologic outcomes after 24 weeks in HIV type-1 infected adolescents receiving highly active antiretroviral therapy. J Infect Dis. 2004; 190:271-279.
22. Karlsson AC, Younger SR, Martin JN, et al. Immunologic and virologic evolution during periods of intermittent and persistent low-level viremia. AIDS. 2004;18:981-989.
23. Castro P, Plana M, Gonzalez R, et al. Influence of episodes of intermittent viremia)blips) on immune responses and viral load rebound in successfully treated HIV-infected patients. AIDS Res Hum Retroviruses. 2013;29:68-76.
24. Ramratnam B, Mittler JE, Zhang L, et al. The decay of the latent reservoir of replication-competent HIV-1 is inversely correlated with the extent of residual viral replication during prolonged anti-retroviral therapy. Nat Med. 2000;6:82-85.
25. Chun T, Murray D, Justement JS, et al. Relationship between residual plasma viremia and the size of HIV proviral DNA reservoirs in infected individuals receiving effective antiretroviral therapy. J Infect Dis. 2011; 204:135-138.
26. Jones LE, Parelson AS. Transient viremia, plasma viral load and reservoir replenishment in HIV-infected patients on antiretroviral therapy. J Acquir Immune Defic Syndr. 2007;45:483-493.